Nicole M Engel-Nitz1, Yanni Hao2, Laura K Becker1, Randall Gerdes1. 1. Senior Researcher, Optum, Health Economics & Outcomes Research, 12125 Technology Drive, Eden Prairie, MN 55344, USA. 2. Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Abstract
AIM: To examine cost and mortality differences in postmenopausal women with HR(+)/HER2(-) advanced breast cancer. METHODS: Using claims data (2007-2013), women with newly diagnosed (de novo) stage IV, or early- or late-recurring metastatic breast cancer were identified. RESULTS: Compared with de novo (n = 121) and late-recurrent (n = 106), early-recurrent (n = 172) patients had significantly higher costs in total and for anticancer systemic agents. Adjusted per patient per month costs for early-recurrent patients were US$13,404, versus US$9955 (de novo) and US$9721 (late-recurrent; p = 0.02). Early-recurrent patients' risk of death was twice that of de novo patients (p = 0.02). CONCLUSION: Compared with new diagnosis or late recurrence, early recurrence of HR+/HER2- metastatic breast cancer was associated with higher mortality and healthcare costs.
AIM: To examine cost and mortality differences in postmenopausal women with HR(+)/HER2(-) advanced breast cancer. METHODS: Using claims data (2007-2013), women with newly diagnosed (de novo) stage IV, or early- or late-recurring metastatic breast cancer were identified. RESULTS: Compared with de novo (n = 121) and late-recurrent (n = 106), early-recurrent (n = 172) patients had significantly higher costs in total and for anticancer systemic agents. Adjusted per patient per month costs for early-recurrent patients were US$13,404, versus US$9955 (de novo) and US$9721 (late-recurrent; p = 0.02). Early-recurrent patients' risk of death was twice that of de novo patients (p = 0.02). CONCLUSION: Compared with new diagnosis or late recurrence, early recurrence of HR+/HER2- metastatic breast cancer was associated with higher mortality and healthcare costs.
Authors: Michael J Hassett; Matthew Banegas; Hajime Uno; Shicheng Weng; Angel M Cronin; Maureen O'Keeffe Rosetti; Nikki M Carroll; Mark C Hornbrook; Debra P Ritzwoller Journal: J Oncol Pract Date: 2019-05-20 Impact factor: 3.840
Authors: A P Nunes; C Liang; W J Gradishar; T Dalvi; J Lewis; N Jones; E Green; M Doherty; J D Seeger Journal: Curr Oncol Date: 2019-04-01 Impact factor: 3.677
Authors: Debra P Ritzwoller; Paul A Fishman; Matthew P Banegas; Nikki M Carroll; Maureen O'Keeffe-Rosetti; Angel M Cronin; Hajime Uno; Mark C Hornbrook; Michael J Hassett Journal: Health Serv Res Date: 2018-07-24 Impact factor: 3.402
Authors: Michael J Hassett; Hajime Uno; Angel M Cronin; Nikki M Carroll; Mark C Hornbrook; Debra P Ritzwoller Journal: JNCI Cancer Spectr Date: 2018-06-28